CONSOLIDATED STATEMENTS OF OPERATIONS (USD $) In Thousands, except Share data, unless otherwise specified	12 Months Ended
	Apr. 30, 2012	Apr. 30, 2011
Operating revenue:
Personalized oncology solutions	$ 2,332	$ 3,382
Translational oncology solutions	4,817	3,500
Total operating revenue	7,149	6,882
Costs and operating expenses:
Cost of personalized oncology solutions	2,356	1,665
Cost of translational oncology solutions	2,543	1,846
Research and development	2,937	2,910
Sales and marketing	2,928	1,085
General and administrative	5,450	4,611
Total costs and operating expenses	16,214	12,117
Loss from operations	(9,065)	(5,235)
Other income:
Grant income	0	1,465
Change in fair value of warrant liability	417	(36)
Other (expense) income	(15)	15
Total other income	402	1,444
Net loss before income tax expense	(8,663)	(3,791)
(Benefit from) provision for income tax	(2)	11
Net loss	$ (8,661)	$ (3,802)
Net loss per common share outstanding, including redeemable common stock, basic and diluted (in dollars per share)	$ (0.19)	$ (0.11)
Weighted average common shares outstanding, including redeemable common stock, basic and diluted (in shares)	46,815,000	33,774,000